IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+3.57%)
Close on Nov 18, 2026Market cap $20.12MP/E –Yield –
IGC Pharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
IGC Pharma's free cash flow for the twelve months ending Mar 31, 2026 was -$5.99M. For fiscal 2025 it was -$4.91M. The highest annual figure on record is $238.77K in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -$4.91M | – |
| FY2024 | Mar 31, 2024 | -$5.34M | – |
| FY2023 | Mar 31, 2023 | -$7.36M | – |
| FY2022 | Mar 31, 2022 | -$7.70M | – |
| FY2021 | Mar 31, 2021 | -$12.27M | – |
| FY2020 | Mar 31, 2020 | -$13.07M | – |
| FY2019 | Mar 31, 2019 | -$3.35M | – |
| FY2018 | Mar 31, 2018 | -$2.07M | – |
| FY2017 | Mar 31, 2017 | -$1.54M | – |
| FY2016 | Mar 31, 2016 | -$279.89K | – |
| FY2015 | Mar 31, 2015 | -$2.66M | – |
| FY2014 | Mar 31, 2014 | -$1.75M | -833.2% |
| FY2013 | Mar 31, 2013 | $238.77K | – |
| FY2012 | Mar 31, 2012 | -$5.03M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$1.22M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$1.24M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$2.12M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$1.42M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$748.00K | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$1.34M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$1.03M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$1.79M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$541.00K | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$1.66M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$1.65M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$1.49M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$2.32M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$971.00K | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$2.45M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$2.33M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$1.94M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.59M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$2.00M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$2.75M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$4.93M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$2.71M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$3.87M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$2.45M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$4.05M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$1.16M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$1.34M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$316.00K | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$538.00K | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$1.08M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$348.00K | -601.4% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$110.22K | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$525.78K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$924.92K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $69.40K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -$881.03K | – |
See a number that looks wrong?